ArticleRespiratory research2026
Qingre Runzao oral liquid and its key compound ophiopogonin D inhibit CXCL9 and block CXCL9/CXCR3 axis to ameliorate asthma by suppressing RAS/ERK pathway.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundQingre Runzao oral liquid (QRRZ) is a Chinese medicine prescription. Previous studies have confirmed its good therapeutic effect on bronchial asthma (BA), but the mechanisms remain unclear. This study aims to clarify the anti-BA effect and mechanisms of QRRZ, and further reveal the key compounds of QRRZ that ameliorate BA.
methodsFirstly, the BA model mice were used to evaluate the therapeutic effect of QRRZ on BA. Then, RNA-seq analysis was performed to reveal the key targets and mechanisms of QRRZ in ameliorating BA, and the results were verified by RT-PCR and Western Blotting. Molecular docking, molecular dynamics simulation, and CETSA were used to screen the key compounds of QRRZ in ameliorating BA. The potential of key compounds on BA was evaluated in vitro. Finally, the mechanisms were verified, and a rescue experiment was conducted.
resultsQRRZ can ameliorate bronchial pathological changes and airway hyperresponsiveness, alleviate the progression of BA by reducing inflammatory cell infiltration, especially neutrophils. QRRZ significantly inhibits the expression of MUC5AC and Th2-related cytokines IL-6 and IL-13 in BALF solution and upregulates the Th1-related cytokine IL-2. RNA-seq results showed QRRZ mainly blocks CXCL9/CXCR3 axis and inhibits RAS/ERK pathway activation to ameliorate BA, and CXCL9 is the key protein of QRRZ. Molecular docking and molecular dynamics simulation results showed that Ophiopogonin D (Oph D) can bind to CXCR3 (CXCL9 receptor) tightly. CETSA and CO-IP assays confirm that Oph D can bind stably to CXCR3. Then, Oph D exhibited potent anti-BA efficacy both in vitro and in vivo. Furthermore, results indicated Oph D can down-regulate CXCL9 and block the CXCL9/CXCR3 axis to inhibit RAS/ERK pathway activation in 16HBE cells.
conclusionQRRZ could block the CXCL9/CXCR3 axis to inhibit RAS/ERK pathway activation, reduce neutrophil infiltration in bronchioles, and improve bronchial asthma. Among these, Oph D is the key component of QRRZ in ameliorating BA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.